Emrelis is a novel ADC targeting the c-Met receptor, a tyrosine kinase implicated in tumor proliferation, metastasis, and resistance in non-squamous non-small cell lung cancer (NSCLC).134 The antibody component binds c-Met with high affinity, enabling selective delivery of the cytotoxic payload to c-Met-overexpressing tumor cells. The gene discussed is MET; the disease is non-small cell lung carcinoma.